1. Home
  2. Browse Decisions
  3. TRIS PHARMA, INC. v. ACTAVIS LABORATORIES FL, INC.
 

TRIS PHARMA, INC. v. ACTAVIS LABORATORIES FL, INC.

Nos. 2017-2557, 2017-2559, 2017-2560.

TRIS PHARMA, INC., Plaintiff-Appellant v. ACTAVIS LABORATORIES FL, INC., Defendant-Appellee

United States Court of Appeals, Federal Circuit.

Decided: November 20, 2018.

Attorney(s) appearing for the Case

ERROL TAYLOR , Milbank, Tweed, Hadley & McCloy, LLP, New York, NY, argued for plaintiff-appellant. Also represented by ANNA BROOK , JORDAN P. MARKHAM , FREDERICK ZULLOW .

WILLIAM M. JAY , Goodwin Procter LLP, Washington, DC, argued for defendant-appellee. Also represented by BRIAN TIMOTHY BURGESS , WILLIAM G. JAMES, II ; DAVID ZIMMER , Boston, MA; ELIZABETH HOLLAND , LINNEA P. CIPRIANO , MICHAEL B. COTTLER , CYNTHIA LAMBERT HARDMAN , TIFFANY MAHMOOD , ALEXANDRA D. VALENTI , New York, NY.

Before NEWMAN, O'MALLEY, and CHEN, Circuit Judges.

This disposition is nonprecedential.

Tris Pharma, Inc. (Tris) holds the approved New Drug Application for Quillivant XR®, an extended release methylphenidate (MPH) formulation for the treatment of Attention Deficit Hyperactive Disorder (ADHD). When Actavis Laboratories, Inc. (Actavis) submitted an Abbreviated...

Let's get started

Leagle.com

Welcome to the leading source of independent legal reporting
Sign on now to see your case.
Or view more than 10 million decisions and orders.

  • Updated daily.
  • Uncompromising quality.
  • Complete, Accurate, Current.

Listed below are the cases that are cited in this Featured Case. Click the citation to see the full text of the cited case. Citations are also linked in the body of the Featured Case.

Cited Cases

  • No Cases Found

Listed below are those cases in which this Featured Case is cited. Click on the case name to see the full text of the citing case.

Citing Cases